Metformin in Breast Cancer: Time for Action
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Pamela J. Goodwin, Samuel Lunenfeld Research Institute, Mount Sinai Hospital; and Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada Jennifer A. Ligibel, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard School of Medicine, Boston, MA Vuk Stambolic, Division of Signaling Biology, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
The PIK3CA gene is mutated with high frequency in human breast cancers
Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.994 · Cited by 665
Alimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7933 · Cited by 523
Cited by
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
“, and a large Phase III clinical trial of metformin as an adjuvant in breast cancer for patients with or without diabetes is in developmen”
BackgroundHirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
“These observations suggest the possibility that metformin might be useful as an anticancer drug in nondiabetic contexts (10, 11).”
BackgroundMetformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Self-citationTriple-negative breast cancer: disease entity or title of convenience?
Carey, L., Winer, E., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 783
Wolin, K. Y., Carson, K., & Colditz, G. A. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0285 · Cited by 778
Lee, C., Zeng, J., Drew, B. G., Sallam, T., Martin-Montalvo, A., Wan, J., Kim, S.-J., Mehta, H., Hevener, A. L., de Cabo, R., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.009 · Cited by 715
Metformin and the Risk of Cancer
Suissa, S., & Azoulay, L. (2012) · Diabetes Care · doi:10.2337/dc12-0788 · Cited by 531
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493
Diabetes Mellitus and Breast Cancer Outcomes: A Systematic Review and Meta-Analysis
Peairs, K. S., Barone, B. B., Snyder, C. F., Yeh, H.-C., Stein, K. B., Derr, R. L., Brancati, F. L., & Wolff, A. C. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3011 · Cited by 449
Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities
Jiralerspong, S., & Goodwin, P. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4480 · Cited by 405
Self-citationAMPK As a Metabolic Tumor Suppressor: Control of Metabolism and Cell Growth
Luo, Z., Zang, M., & Guo, W. (2010) · Future Oncology · doi:10.2217/fon.09.174 · Cited by 383
Inflammatory Breast Cancer: The Disease, the Biology, the Treatment
Robertson, F. M., Bondy, M., Yang, W., Yamauchi, H., Wiggins, S., Kamrudin, S., Krishnamurthy, S., Le-Petross, H., Bidaut, L., Player, A. N., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20082 · Cited by 366
Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Sadeghi, N., Abbruzzese, J. L., Yeung, S.-C. J., Hassan, M., & Li, D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2994 · Cited by 305
Associations of Insulin Resistance and Adiponectin With Mortality in Women With Breast Cancer
Duggan, C., Irwin, M. L., Xiao, L., Henderson, K. D., Smith, A. W., Baumgartner, R. N., Baumgartner, K. B., Bernstein, L., Ballard-Barbash, R., & McTiernan, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4473 · Cited by 294
Drug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
Donadon, V., Balbi, M., Mas, M. D., Casarin, P., & Zanette, G. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02223.x · Cited by 292
Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes
Zhang, Z.-J., Zheng, Z.-J., Kan, H., Song, Y., Cui, W., Zhao, G., & Kip, K. E. (2011) · Diabetes Care · doi:10.2337/dc11-0512 · Cited by 291
Bao, B., Ahmad, A., Azmi, A. S., Ali, S., & Sarkar, F. H. (2013) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1425s61 · Cited by 286
Storozhuk, Y., Hopmans, S. N., Sanli, T., Barron, C., Tsiani, E., Cutz, J.-C., Pond, G., Wright, J., Singh, G., & Tsakiridis, T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.187 · Cited by 273
Impact of Age, Sex, and Comorbidity on Cancer Therapy and Disease Progression
Pal, S. K., & Hurria, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0579 · Cited by 265
EMT: Present and future in clinical oncology
Santamaria, P. G., Moreno‐Bueno, G., Portillo, F., & Cano, A. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12091 · Cited by 259
Energy Balance, Host-Related Factors, and Cancer Progression
Hursting, S. D., & Berger, N. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.27.9935 · Cited by 252
Glucose Promotes Breast Cancer Aggression and Reduces Metformin Efficacy
Wahdan-Alaswad, R., Fan, Z., Edgerton, S. M., Liu, B., Deng, X.-S., Arnadottir, S. S., Richer, J. K., Anderson, S. M., & Thor, A. D. (2013) · Cell Cycle · doi:10.4161/cc.26641 · Cited by 125
“Epidemiological data indicate that metformin has unique anti-cancer activity, reducing risk and improving survival.(13,20,29-34) Limited retrospective data also suggests that metformin may improve response to chemotherapy.”
BackgroundInfluentialFriedenreich, C. M., Neilson, H. K., Woolcott, C. G., McTiernan, A., Wang, Q., Ballard-Barbash, R., Jones, C. A., Stanczyk, F. Z., Brant, R. F., Yasui, Y., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0303 · Cited by 124
“Differing levels of evidence support roles for these proposed biomarkers in breast cancer, but the greatest pool of epidemiologic data in postmenopausal women exists for insulin (Gunter et al. 2009, Kabat et al. 2009, Neilson et al. 2009) and IGF1 and its binding proteins (Key et al. 2010).”
BackgroundInfluentialLiu, B., Fan, Z., Edgerton, S. M., Yang, X., Lind, S. E., & Thor, A. D. (2011) · Cell Cycle · doi:10.4161/cc.10.17.16359 · Cited by 120
Phenformin as prophylaxis and therapy in breast cancer xenografts
Appleyard, M. V. C. L., Murray, K. E., Coates, P. J., Wullschleger, S., Bray, S. E., Kernohan, N. M., Fleming, S., Alessi, D. R., & Thompson, A. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.56 · Cited by 108
Metformin and Cancer: Mounting Evidence Against an Association
Suissa, S., & Azoulay, L. (2014) · Diabetes Care · doi:10.2337/dc14-0500 · Cited by 93
Metformin and cancer: licence to heal?
Papanas, N., Maltezos, E., & Mikhailidis, D. P. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.499122 · Cited by 37
“Although the exact mechanism(s) mediating the protective action of metformin need further clarification, some authors have already suggested that this drug may prove useful as an adjunctive antitumor agent [28,32,38,39], including nondiabetic patients [39].”
BackgroundInfluentialColon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis
Rokkas, T., & Portincasa, P. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.05.027 · Cited by 34
Bardella, C., Olivero, M., Lorenzato, A., Geuna, M., Adam, J., O'Flaherty, L., Rustin, P., Tomlinson, I., Pollard, P. J., & Di Renzo, M. F. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06160-11 · Cited by 33
Metadata
- Authors
- Goodwin, P. J., Ligibel, J. A., & Stambolic, V.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-10
- Volume
- 27
- Issue
- 20
- Pages
- 3271-3273
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1988342283
- Cited by
- 200
- References
- 7
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.